Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension

Pfeiffer, Norbert

doi:10.1007/s00417-011-1650-8

Cited by 19 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The comparative efficacy of adjunctive therapy with brinzolamide þ TRAV or brimonidine þ TRAV compared with TRAV monotherapy has been evaluated in several prospective, randomized, masked studies of patients with open-angle glaucoma or ocular hypertension. [16][17][18][19] These studies demonstrated that adjunctive therapy with either brinzolamide or brimonidine was more efficacious than TRAV alone. In a trial with similar design and treatment duration compared with the current study, mean diurnal IOP reductions from TRAV-treated baseline levels were À2.8 mm Hg and À2.1 mm Hg with brinzolamide þ TRAV and brimonidine þ TRAV, respectively.…”

Section: Control Of Iop Is Required To Reduce the Rate Of Pro-mentioning

confidence: 91%

A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%

Feldman

Katz

McMenemy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Control Of Iop Is Required To Reduce the Rate Of Pro-mentioning

confidence: 91%

A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%

Feldman

Katz

McMenemy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…20,30 The evidence regarding which of the IOP-lowering effects is more intensive between b-blockers and another CAI, brinzolamide, however, is conflicting. 31,32 The present study revealed that topical brinzolamide was more effective than timolol for reducing the short-term IOP increase after cataract surgery.…”

Section: Resultsmentioning

confidence: 57%

Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma

Hayashi

Yoshida

et al. 2019

American Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE: To compare the effects of a topical intraocular pressure (IOP)-lowering medication for preventing an IOP increase after cataract surgery in eyes with glaucoma. DESIGN: Randomized clinical study. METHODS: A total of 165 eyes of 165 patients with primary open-angle glaucoma or pseudoexfoliation glaucoma scheduled for phacoemulsification were randomly assigned to 1 of 3 groups to receive each medication immediately postoperatively: 1) prostaglandin F 2a analog (travoprost), 2) b-blocker (timolol maleate), or 3) carbonic anhydrase inhibitor (brinzolamide). Intraocular pressure (IOP) was measured using a rebound tonometer at 1 hour preoperatively, at the end of surgery, and at 2, 4, 6, 8, and 24 hours postoperatively. The incidence of eyes exhibiting a marked IOP increase to greater than 25 mm Hg was compared among the groups. RESULTS: At 1 hour preoperatively and at the end of surgery, mean IOP did not differ significantly among the groups. Mean IOP increased significantly between 4 and 8 hours postoperatively and then decreased at 24 hours postoperatively in all groups (P < .0001). Mean IOP was significantly lower in the brinzolamide group than in the travoprost or timolol group at 4, 6, and 8 hours postoperatively (P £ .0374) and did not differ significantly among groups at 2 and 24 hours postoperatively. The incidence of an IOP spike was significantly lower in the brinzolamide group than in the travoprost and timolol groups (P [ .0029). CONCLUSIONS: Brinzolamide reduces the short-term IOP increase after cataract surgery more effectively than travoprost or timolol in eyes with glaucoma, suggesting that brinzolamide is preferable for preventing an IOP spike.

show abstract

“…The basic characteristics of the included studies were shown in Supplementary Table 1 . All trials were randomized and active-controlled involving the study drugs added on PAG in 11 articles (Hollo et al, 2006; Reis et al, 2006; Feldman et al, 2007; Day and Hollander, 2008; Miura et al, 2008; Bournias and Lai, 2009; Nakamura et al, 2009; Pfeiffer, 2011; Konstas et al, 2013; Alcon, 2016; Aihara et al, 2017), added on timolol 0.5% in two articles (Michaud and Friren, 2001; Martinez and Sanchez-Salorio, 2009), and added on the combination therapy of latanoprost and a beta-blocker in one article (Tsukamoto et al, 2005). Main clinical diagnosis of patients were POAG and OHT; a few were other glaucoma (exfoliation glaucoma, pigmentary glaucoma).…”

Section: Resultsmentioning

confidence: 99%

“…All studies were randomized, multicenter clinical trials; six trials (Silver, 1998; Miura et al, 2008; Bournias and Lai, 2009; Manni et al, 2009; Katz et al, 2013; Aung et al, 2014) described the sequence generation. Twelve studies (Silver, 1998; Sall, 2000; March and Ochsner, 2000; Hollo et al, 2006; Feldman et al, 2007; Day and Hollander, 2008; Kaback et al, 2008; Miura et al, 2008; Bournias and Lai, 2009; Pfeiffer, 2011; Katz et al, 2013; Aung et al, 2014) offer the details of concealment procedures (Martinez and Sanchez-Salorio, 2009; Research, 2013a; Research, 2013b; Alcon, 2016). Sixteen trials performed ITT analyses (Sall, 2000; March and Ochsner, 2000; Michaud and Friren, 2001; Hollo et al, 2006; Feldman et al, 2007; Kaback et al, 2008; Bournias and Lai, 2009; Martinez and Sanchez-Salorio, 2009; Manni et al, 2009; Pfeiffer, 2011; Research, 2013a; Research, 2013b; Katz et al, 2013; Nguyen et al, 2013; Whitson et al, 2013; Aung et al, 2014) and all studies described withdraws or dropouts.…”

Section: Resultsmentioning

confidence: 99%

“…In the present systematic review, we assessed 26 RCTs, containing a comparison between brinzolamide and timolol in 7 studies (Silver, 1998; March and Ochsner, 2000; Hollo et al, 2006; Reis et al, 2006; Kaback et al, 2008; Miura et al, 2008; Pfeiffer, 2011), brinzolamide and dorzolamide in 10 studies (Sall, 2000; Michaud and Friren, 2001; Tsukamoto et al, 2005; Bournias and Lai, 2009; Martinez and Sanchez-Salorio, 2009; Manni et al, 2009; Nakamura et al, 2009; Sezgin Akcay et al, 2013; Alcon, 2016; Aihara et al, 2017), and brinzolamide and brimonidine in 9 studies (Feldman et al, 2007; Day and Hollander, 2008; Katz et al, 2013; Konstas et al, 2013; Nguyen et al, 2013; Research, 2013a; Research, 2013b; Whitson et al, 2013; Aung et al, 2014). Patients with POAG or OHT have a common characteristic as elevated IOP, which is closely associated with progression of visual field deterioration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but the efficacy was controversial. So, this study was used to assess the efficacy and safety of brinzolamide as add-on to prostaglandin analogues (PGAs) or β-blocker in treating patients with glaucoma or OHT who fail to adequately control IOP. Methods: We searched PubMed, Embase, MEDLINE, Cochrane Library, and clinicaltrials.gov from inception to October 4, 2018. Randomized controlled trials of brinzolamide as add-on to PGAs or β-blocker for glaucoma and OHT were included. Meta-analysis was conducted by RevMan 5.3 software. Results: A total of 26 trials including 5,583 patients were analyzed. Brinzolamide produced absolute reductions of IOP as an adjunctive therapy for patients with glaucoma or OHT. Brinzolamide and timolol were not significantly different in lowering IOP as add-on to PGAs (9 am: P = 0.07; 12 am: P = 0.66; 4 pm: P = 0.66). Likewise, brinzolamide was as effective as dorzolamide in depressing IOP (9 am: P = 0.59; 12 am: P = 0.94; 4 pm: P = 0.95). For the mean diurnal IOP at the end of treatment duration, there were no statistical differences in above comparisons ( P > 0.05). Compared with brimonidine (b.i.d.), there was a significant reduction of IOP in brinzolamide (b.i.d.) at 9 am ( P < 0.0001); however, the difference was cloudy in thrice daily subgroup ( P = 0.44); at 12 am, brinzolamide (b.i.d.) was similar to brimonidine (b.i.d.) in IOP-lowering effect ( P = 0.23), whereas brimonidine (t.i.d.) led to a greater effect than brinzolamide (t.i.d.) ( P = 0.02). At 4 pm, brinzolamide (b.i.d.) was superior IOP-lowering effect compared with brimonidine (b.i.d.) ( P = 0.0003); conversely, the effect in brinzolamide (t.i.d.) was lower than brimonidine (t.i.d.) ( P < 0.0001). For the mean diurnal IOP, brinzolamide was lower in twice daily subgroup ( P < 0.00001); brimonidine was lower in thrice daily subgroup ( P < 0.00001). With regard to the safety, brinzolamide and dorzolamide had a higher incidence of taste abnormality; moreover, brinzolamide resulted in more frequent blurred vision; dorzolamide resulted in more frequent ocular discomfort and eye pain. Timolol resulted in more frequent blurred vision and less conjunctival hyperemia. Brimonidine resulted in more frequent ocular hyperemia. As to other adverse events (AEs) (conjunctivitis, eye pruritus, foreign body sensation in eyes, and treatment-related AEs), brinzolamide was similar to other three active comparators. Conclusions: Brinzolamide, as ad...

show abstract

Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension

Cited by 19 publications

References 24 publications

A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%

A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%

Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma

Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About